Active Biotech (ACTI) investor relations material

Strategy and portfolio

• Focused immunomodulatory pipeline in oncology and inflammation: tasquinimod for haematological malignancies and laquinimod for inflammatory eye disorders.

• Tasquinimod is the core clinical focus in myelofibrosis; laquinimod eye-drop development is continuing with a partner.

• FDA Orphan Drug Designation granted for tasquinimod in myelofibrosis and multiple myeloma; patent protection for tasquinimod and laquinimod extends into the 2040s.

Tasquinimod in myelofibrosis

• Two clinical studies are ongoing: TasqForce Phase Ib/II (N=20) and a Phase II study at MD Anderson (N=33), both evaluating monotherapy in patients ineligible or intolerant to JAK inhibitors.

• TasqForce reported its first safety cohort; recommended Phase II dose expected 2027Q1 and interim results 2027Q4. MD Anderson interim results expected 2027Q4.

• TasqForce primary endpoint is spleen volume reduction >35% at week 24; MD Anderson’s primary endpoint is objective response rate at week 24.

• Preclinical studies indicate tasquinimod can reduce spleen size and fibrosis, normalize leukocytosis and prolong survival; combination studies showed enhanced JAK and BET inhibitor effects.

• Myelofibrosis market size across seven major markets estimated at $2.6B for 2025; top-eight-market revenue potential projected above $5B by 2036.

Laquinimod for eye disorders

• Phase I safety and ocular biodistribution studies of the proprietary hydrogel eye-drop formulation completed; patent protection for medical use, manufacturing and formulation extends through 2042.

• In the LION study, 14 days of eye-drop treatment was safe and well tolerated, with dose-related, therapeutically relevant laquinimod concentrations in the anterior chamber and vitreous.

• Non-anterior non-infectious uveitis is a target indication; the presentation cites ~550,000 addressable patients and a $1.5B market opportunity by 2031.

• Phase II development in uveitis is subject to partnering; continued clinical development is planned with a partner toward a registrational Phase II/III study.